Tests developed using the Q-LAAD technology ecosystem designed to be plug-and-play, requiring minimal adaptation time associated with new test development and we can quickly design tests that detect a range of molecules.
In recent clinical trials, our Q-LAAD SARS-CoV-2 test demonstrated a combination of speed, accuracy, & ease-of-use that cannot be achieved with legacy testing technologies (PCR, antigen, etc.). Tests take less than 5 minutes of analyzer time and still yield 97% sensitivity and 100% specificity*
*This data has not been verified by the FDA or any other regulatory body.
Q-LAAD technology can be adapted to a variety of testing formats. Although our testing ecosystem will be adapted to a point-of-care format, Q-LAAD technology can be used to develop tests for use in hospital labs with commercially available analyzers that fit within standard medical laboratory workflows, requiring minimal training or new expertise.
A New Biodiagnostic Paradigm
In addition to our revolutionary Q-LAAD test, we are developing a proprietary analyzer enabling simple plug-and-play tests that can be administered at the point of care. These point-of-use Q-LAAD tests allow us to deliver on our mission to provide lab-grade quality diagnostics to those who are in the most need regardless of geography or socioeconomic status.
Be a part of the revolution
We are currently raising capital via a Regulatory A+ securities offering. As an early-stage investor, you can help Facible revolutionize diagnostic testing for people around the world. For a limited time, early investors have the opportunity to earn one bonus share for every share purchased.Invest Now